UAMS Celebrates Opening of 10-story High-Tech Hospital

University of Arkansas for Medical Sciences (UAMS) supporters, patients and their families today celebrated the opening of a 540,000-square-foot hospital replacing most of the patient care services in the original 52-year-old UAMS Medical Center building.

The 10-level, nearly $200 million building incorporates the latest medical technology, larger all-private patient rooms and private rooms for infants in the neonatal intensive care unit (NICU). Other design elements focus on creating a pleasant environment that promotes healing and provides ample space for family members to support loved ones during a hospital stay.

Patients will be moved from the old building into the new facility Jan. 17 and 18.

“Today marks an exciting milestone in the history of UAMS and health care in Arkansas as we open our new hospital, allowing us to replace an outdated, outgrown and more than 50-year-old hospital building,” said Richard Pierson, UAMS vice chancellor for clinical programs and UAMS Medical Center executive director. “The quality of the facility now matches the quality of the care our terrific physicians and staff provide.”

Read More...

Actor Mary Steenburgen speaks at the hospital dedication. To her right are Gov. Mike Beebe and UAMS Medical Center COO Melissa Fontaine.

Osteoporosis Drug Research in Journal

Researchers at the University of Arkansas for Medical Sciences (UAMS) have found that a common drug treatment for osteoporosis raises new questions about how the drug affects certain bone cells.

In a study published Jan. 1 by the New England Journal of Medicine, UAMS researchers found that postmenopausal women who took the drug bisphosphonate alendronate (Fosamax) for up to three years had an increase in their number of osteoclasts, the cells responsible for removing bone.

Postmenopausal osteoporosis results from an imbalance in the cells responsible for removing old bone (osteoclasts) and replacing it with new, stronger bone (osteoblasts).

Fosamax, part of a class of drugs known as bisphosphonates, is thought to prevent the imbalance by decreasing the number of bone-eroding cells (osteoclasts).

But UAMS and Central Arkansas Veterans Healthcare System researchers, led by Robert S. Weinstein, M.D., found that the alendronate bisphosphonate treatment significantly increases the number of osteoclasts.

Read More...

LATE BREAKING NEWS
	Wei Named Executive Director of Institute on Aging Patient Receives Stents and Bypass – a UAMS First UAMS BioVentures Company to Market Cost-Cutting Services for Pharmacy Benefit Programs UAMS Psychiatric Research Institute-Northwest Names Medical Director, Clinical Manager

LINKS OF INTEREST
	Erectile Seminar Dysfunction Feb. 10 Check Out the New UAMS Patient Website. Discover Your Career For Life Lose Weight with UAMS. Try Out Our Interactive Tools Watch Us Grow! Construction Accelerates on Campus Travel Medicine Consulting Services and Vaccinations How to Order Your Cure Breast Cancer License Plate UAMS' Here's to Your Health Radio Broadcasts with Dr. T. Glenn Pait

View Last Month's Newsletter...

View Past Newsletters...



UAMS on